Distressful journey for the metabolic syndrome to its position in clinical practice

Czech version

Authors: J. Rybka
Authors‘ workplace: Diabetologické centrum Interní kliniky IPVZ Krajské nemocnice T. Bati, a. s., Zlín, přednosta doc. MUDr. Čestmír Číhalík, CSc.
Published in: Vnitř Lék 2010; 56(7): 727-735
Category: 80th Birthday - Jaroslava Blahoše, MD, DrSc.

Overview

MS is a major atherogenic syndrome in our population. The concept of MS has had a very positive effect on our knowledge of the most serious civilization diseases, the genotypic constellation of MS, although monogenic defects explain only a very small part of pathological defects. It is certain, however, that a crucial role played is by interactions between genetic factors and risk factors of external environment. Undoubtedly, insulin resistance, central obesity and impaired metabolism of adipose tissue play an important role in the pathogenesis of MS, and there are other pathogenetic theories. The author discusses briefly the history of MS and presents the best‑known definitions starting with the 90s of the last century, ADA and EASD reservations towards MS, as well as the new harmonized definition from 2009. This modified definition of MS has been adopted in practice in the Czech Republic due to the Czech Institute of metabolic syndrome. The author discusses in greater detail the WHO expert report from 2010, which indicates some limitations of diagnostic criteria for MS. Despite all the objections the expert report provides reasons to support the use of the term metabolic syndrome, and metabolic syndrome is considered to be a recognized concept that focuses attention on the importance of comprehensive, multifactorial health problems. Finally, the author mentions sub‑problems related to MS, which will have to be resolved in collaboration with diabetologists.

Key words:
metabolic syndrome – history of MS – evolutionary perspective – insulin resistance – definitions – WHO expert consultation report on MS – prediabetes and MS

Sources

1. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745–2749.

2. Mokan M, Galajda P, Prídavková D et al. Prevalence of diabetes mellitus and metabolic syndrome in Slovakia. Diabetes Res Clin Pract 2008; 81: 238–242.

3. West KM. Substantial differences in the diagnostic criteria used by diabetic experts. Diabetes 1975; 24: 641–644.

4. Himsworth H. Diabetes mellitus: a differentiation into insulin‑sensitive and insulin‑insensitive types. Lancet 1936; i: 127–130.

5. Kylin E. Studien über das Hypertonie – Hyperglykämie – Hyperurikämiesyndrom. Zentralblatt für Innere Medizin 1923; 44: 105–127.

6. Vague J. La différenciation sexuelle, facteur déterminant des formes de l’obésité. Presse Med 1947; 30: 339–340.

7. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956; 4: 20–34.

8. Ashwell M, Cole TJ, Dixon AK. Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography. Br Med J 1985; 290: 1692–1694.

9. Kaplan NM. The deadly quartet. Upper‑-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514–1520.

10. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.

11. Björntorp P. Abdominal obesity and the metabolic syndrome. Ann Med 1992; 24: 465–468.

12. Sucharda P. Obezita a metabolický syndrom. Od syndromu inzulinové rezistence k „syndromu centrální obezity“? Interní Med 2008; 10: 165–166.

13. Galajda P, Mokáň M. Metabolický syndrom X – otázky pre nové milénium. Diabetes a obezita 2001; 1: 9–15.

14. Marks JB. Metabolic Syndrome: To Be or Not To Be? Clin Diabetes 2006; 24: 3–4.

15. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214–E223.

16. Simmons RK, Alberti KG, Gale EA et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010; 53: 600–605.

17. Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006; 83: 1237–1247.

18. Neel JV. Diabetes mellitus „a thrifty“ genotype rendered detrimental by „progress“? Am J Hum Genet 1962; 14: 353–362.

19. Waterland RA, Garza C. Potential mechanisms of metabolic imprinting that lead to chronic disease. Am J Clin Nutr 1999; 69: 179–197.

20. Barker DJ. In utero programming of chronic disease. Clin Sci 1998; 95: 115–128.

21. Lucas A. Role of nutritional programming in determining adult morbidity. Arch Dis Child 1994; 71: 288–290.

22. Sjögren M, Lyssenko V, Jonsson A et al. The search for putative unifying genetic factors for components of the metabolic syndrome. Diabetologia 2008; 51: 2242–2251.

23. Gale EA. The changing phenotype of the human species (affluent variety). Diabetologia 2004; 47: 1339–1342.

24. United Nations. The Millennium Development Goals report 2008. New York: United Nations 2008.

25. Pelikánová T, Vlasáková Z. Metabolický syndrom (syndrom inzulinové rezistence). In: Pelikánová T, Bartoš V (eds). Praktická diabetologie. 4. vyd. Praha: Maxdorf 2010: 101–114.

26. Zeman M, Žák A, Vecka M et al. Inzulínová rezistence, metabolický syndrom a kardiovaskulární onemocnění. Čas Lék Čes 2005; 144 (Suppl 1): 19–26.

27. Cameron AJ, Magliano DJ, Zimmet PZ et al. The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. J Intern Med 2008; 264: 177–186.

28. Canoy D. Distribution of body fat and risk coronary heart disease in men and women. Curr Opin Cardiol 2008; 23: 591–598.

29. Mendis S, Lindholm LH, Mancia G et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction chart: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle‑income countries. J Hypertens 2007; 25: 1578–1582.

30. Duška F. Inzulinová rezistence u kriticky nemocných: molekulární pozadí a metabolické důsledky. DMEV 2005; 8: 119–124.

31. Carr DB, Utzschneider KM, Hull RL et al. Intra‑abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087–2094.

32. Úvod – metabolický syndrom a PPAR. In: Haluzík M, Svačina Š (eds). Metabolický syndrom a nukleární receptory – PPAR. Praha: Grada Publishing 2005: 11–12.

33. Kahn R, Buse J, Ferrannini E et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48: 1684–1699.

34. Carr DB, Utzschneider KM, Hull RL et al. Intra‑abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087–2094.

35. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415–1428.

36. Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator‑activated receptor‑  on progression of insulin resistance and cardiovascular disease. Am J Cardiol 2003; 92 (Suppl 4A): 3J–9J.

37. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–1645.

38. Kahn R, Buse J, Ferrannini E et al. American Diabetes Association, European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289–2304.

39. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

40. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world‑wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–480.

41. Borch‑Johnsen K, Wareham N. The rise and fall of the metabolic syndrome. Diabetologia 2010; 53: 597–599.

42. Rybka J. Diskutované téma: syndrom inzulinové rezistence – metabolický syndrom. PL 2006; 86: 427–428.

43. Rybka J. Odborníci diskutují nad metabolickým syndromem. Medical Tribune 2006; 10.

44. Gale EA. The myth of the metabolic syndrome. Diabetologia 2005; 48: 1679–1683.

45. Reaven GM. The individual components of the metabolic syndrome: is there a raison d’etre. J Am Coll Nutr 2007; 26: 191–195.

46. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem 2005; 51: 931–938.

47. Svačina Š. Existuje metabolický syndrom? Lék listy 2009; 4: 34.

48. Wilkin T. The metabolic syndrome, babies and bathwater. Diabetologia 2006; 49: 421–422.

49. Ford ES. Risks for all‑cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769–1778.

50. Sattar N, McConnachie A, Shaper AG et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371: 1927–1935.

51. Stern MP, Williams K, Gonzáles‑Villalpando C et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 2676–2681.

52. Qiao Q. DECODE Study Group. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006; 49: 2837–2846.

53. Kohli P, Greenland P. Role of the metabolic syndrome in risk assessment for coronary heart disease. JAMA 2006; 295: 819–821.

54. Sucharda P. Metabolický syndrom, jeho význam a používání. Medicína po promoci 2010; 11 (Suppl 1): 3–7.

55. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60, 329–339.

56. Narayan KM. „Polypill“ for cardiovascular disease prevention. Clin Diabetes 2004; 22: 157–158.

57. Ford ES. Risks for all‑cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769–1778.

58. Sattar N, McConnachie A, Shaper AG et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008; 371: 1927–1935.

59. Eddy DM, Schlessinger L, Heikes K. The metabolic syndrome and cardiovascular risk: implications for clinical practice. Int J Obes 2008; 32 (Suppl 2): S5–S10.

60. Carr DB, Utzschneider KM, Hull RL et al. Intra‑abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087–2094.

61. Lee CM, Huxley RR, Woodward M et al. The metabolic syndrome identifies a heterogeneous group of metabolic component combinations in the Asia‑Pacific region. Diabetes Res Clin Pract 2008; 81: 377–380.

62. Franco OH, Massaro JM, Civil J et al. Trajectories of entering the metabolic syndrome: the Framingham heart study. Circulation 2009; 120: 1943–1950.

63. Mancia G, Bombelli M, Corrao G et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 40–47.

64. Stevens J, McClain JE, Truesdale KP. Selection of measures in epidemiologic studies of the consequences of obesity. Int J Obes 2008; 32 (Suppl 3): S60–S66.

65. Canoy D. Distribution of body fat and risk coronary heart disease in men and women. Curr Opin Cardiol 2008; 23: 591–598.

66. Després JP, Lemieux I, Bergeron J et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039–1049.

67. Ruberg FL, Chen Z, Hua N et al. The relationship of ectopic lipid accumulation to cardiac and vascular function in obesity and metabolic syndrome. Obesity 2010; 18: 1116–1121.

68. Karen I, Souček M, Bláha V et al. Metabolický syndrom – diagnostika a léčba. Doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře. Novelizace 2010. Praha: Společnost všeobecného lékařství 2010.

69. Sucharda P. Metabolický syndrom, jeho diagnostika a možnosti léčby. Medicína pro praxi 2010; 7: 111–114.

70. Ford ES, Abbasi F, Reaven GM. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 2005; 181: 143–148.

71. Reaven GM. Is diagnosing metabolic syndrome a uniquely simple way to predict incident type 2 diabetes mellitus? CMAJ 2009; 180: 601–602.

72. American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care 2009; 32 (Suppl 1): S13–S61.

73. Nathan DM, Davidson MB, DeFronzo RA et al. American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753–759.

74. Rybka J. Prediabetes – 2009. Vnitř Lék 2009; 55: 819–826.

75. Ridker PM, Libby P. 36 Risk Factors for Atherothrombotic Disease. In: Braunwald (ed). Braunwald’s Heart Disease. Philadelphia: Elsevier 2005: 939–958

76. Qiao Q. DECODE Study Group. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006; 49: 2837–2846.